Evidence map›Paper›PMID 34382311›Full record

ArticleCancer science2021

Prognostic significance of human papillomavirus 16 viral load level in patients with oropharyngeal cancer.

Yumiko Hashida, Tomonori Higuchi, Shuichi Matsumoto, Mitsuko Iguchi, Ichiro Murakami, Masamitsu Hyodo, Masanori Daibata

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yumiko HashidaDepartment of Microbiology and Infection, Kochi Medical School, Kochi University, Nankoku, Japan.ORCID https://orcid.org/0000-0002-6300-3458
Tomonori HiguchiDepartment of Microbiology and Infection, Kochi Medical School, Kochi University, Nankoku, Japan.
Shuichi MatsumotoDepartment of Otolaryngology, Head and Neck Surgery, Kochi Medical School, Kochi University, Nankoku, Japan.
Mitsuko IguchiDepartment of Pathology, Kochi Medical School, Kochi University, Nankoku, Japan.
Ichiro MurakamiDepartment of Pathology, Kochi Medical School, Kochi University, Nankoku, Japan.
Masamitsu HyodoDepartment of Otolaryngology, Head and Neck Surgery, Kochi Medical School, Kochi University, Nankoku, Japan.
Masanori DaibataDepartment of Microbiology and Infection, Kochi Medical School, Kochi University, Nankoku, Japan.ORCID https://orcid.org/0000-0001-8714-2068
Kōchi University · JP

Funding

Japan Society for the Promotion of Science 19K17928Japan Society for the Promotion of Science 20K08714
6 · The paper itself

Abstract

Human papillomavirus (HPV) infection in patients with oropharyngeal squamous cell carcinoma (OPSCC) is a major determinant for better prognosis. However, there remain HPV-positive patients who have poor outcomes. The stratification strategy for detecting high-risk patients among those with HPV-positive OPSCC has not been well delineated, especially for Asian patients. We undertook a retrospective cohort study on the survival rate of 89 Japanese patients diagnosed with primary OPSCC. The tumors were concurrently analyzed for the presence of HPV E6 DNA/mRNA, viral DNA load, p16 expression, viral physical status, and viral variant lineage. Human papillomavirus 16 viral DNA was found in 45 (51%) OPSCCs. Human papillomavirus 16 DNA-positive OPSCCs with higher viral load (classified as HPV16 DNA-medium/high OPSCCs) showed significantly favorable overall survival and progression-free survival compared with HPV16 DNA-positive OPSCCs with lower viral load (<10 copies/cell; HPV16 DNA-low OPSCCs) and HPV16 DNA-negative OPSCCs. E6 mRNA expression was observed in all HPV16 DNA-medium/high OPSCCs but not in HPV16 DNA-low OPSCCs. Notably, p16-positive and HPV16 DNA-negative/low OPSCCs showed significantly worse survival than p16-positive and HPV16 DNA-medium/high OPSCCs and resembled HPV-unrelated OPSCCs with regard to survival and risk factor profile. Although not significant, a trend toward shorter survival was observed for HPV16-integrated OPSCCs. Phylogenetic analysis revealed two major types of HPV16 variants termed Asian (A4) and European (A1/A2/A3) variants, but no difference in survival between these variants was observed. Altogether, these findings suggest that HPV viral load is a potentially informative factor for more accurate risk stratification of patients with OPSCC.

Indexed as

Viral LoadAdultAgedAged, 80 and overDNA, ViralFemaleGenotypeHuman papillomavirus 16Human papillomavirus 6HumansJapanMaleMiddle AgedOncogene Proteins, ViralOropharyngeal NeoplasmsPhylogenyDNA, ViralE6 protein, Human papillomavirus type 6Oncogene Proteins, ViralRNA, MessengerRNA, Viralhuman papillomavirusJapanese cohortoropharyngeal cancerprognosisviral load

Identifiers

PMID34382311
PMCPMC8486212
OpenAlexW3189653046

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.